A Phase 2 interventional study of Filgrastim and Sodium chloride solution in Acute Ischemic Stroke, sponsored by Sygnis Bioscience GmbH & Co KG. Completed at 58 sites in 7 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-12-13.
Sponsored by Sygnis Bioscience GmbH & Co KG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.
Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 43rd largest by enrollment of the 101 interventional ones that give a count, is one of 9 that started in 2009, is one of 28 in phase 2, and was the 23rd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:
Ludwig-Maximilians - University of Munich · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Takeda · Sites in Germany, United States, Belgium and 7 more countries
Ages 18+
University Hospital Heidelberg · Sites in Germany
Ages 60+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 33 · Phase 3 22 · Phase 4 4
First in 2000; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 328 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 223 across the 101 interventional studies, 410 across the 61 observational. Of the 98 that completed or were terminated, 24 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 164 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sygnis Bioscience GmbH & Co KG as lead sponsor.
Sygnis Bioscience GmbH & Co KG has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
14 of the studies in Ischemic Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04412187Martin DichgansInflammatory faCtors AfteR acUte Ischemic Stroke | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 164 studies in Ischemic Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Filgrastim
Drug: Sodium chloride solution
135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
Improvement on mRS relative to placebo-treated patients
Time frame: day 90
Improvement on NIHSS relative to placebo-treated patients
Time frame: day 90
The record gives a start of May 2009, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim